Johnson & JohnsonJNJ
Briefing quotidien des marchés
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Dernier briefing
Johnson & Johnson's stock declines 0.65% to $260.35 amid market fluctuations.
In the past 24 hours, Johnson & Johnson's stock experienced a slight decline of 0.65%, closing at $260.35. This movement reflects broader market fluctuations rather than company-specific news.
Briefings précédents
Johnson & Johnson's stock rises 0.48% to $262.08 amid steady market performance.
Over the past 24 hours, Johnson & Johnson's stock has experienced a modest increase of 0.48%, closing at $262.08. This uptick reflects the company's stable market performance, with no significant news or events impacting its stock price during this period.
No significant market-moving news for Johnson & Johnson in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Johnson & Johnson's stock performance. The company continues to focus on its core pharmaceutical and medical device operations. Investors should monitor upcoming earnings reports and industry news for potential impacts on the stock.
No significant market-moving news for Johnson & Johnson (JNJ) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Johnson & Johnson's stock performance. The company continues to maintain its position in the healthcare sector without notable news impacting its market standing.
Johnson & Johnson's stock rises 0.97% to $261.81 amid steady market performance.
Over the past 24 hours, Johnson & Johnson's stock has experienced modest fluctuations, closing at $261.81 on August 10, 2026. The market remains relatively stable, with no significant news impacting the stock's performance.
No significant market-moving news for Johnson & Johnson (JNJ) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Johnson & Johnson's stock performance. The company continues to operate across its three main segments: Pharmaceuticals, MedTech, and Consumer Health. Investors should monitor upcoming earnings reports and industry news for potential impacts on JNJ's performance.
Johnson & Johnson's stock rises 0.89% to $259.24 amid steady performance
Over the past 24 hours, Johnson & Johnson's stock has experienced a modest increase of 0.89%, closing at $259.24. This uptick reflects the company's consistent performance, with no significant market-moving news reported during this period.
No significant market-moving news for Johnson & Johnson (JNJ) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Johnson & Johnson's stock performance. The company continues to face ongoing litigation related to its talc-based products, but no new updates have emerged. Traders should monitor upcoming earnings reports and any announcements regarding the company's legal proceedings for potential market impacts.
No significant market-moving news for Johnson & Johnson in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Johnson & Johnson's stock performance. The company continues to focus on its core pharmaceutical and medical device operations. Traders should monitor upcoming earnings reports and industry news for potential impacts on the stock.
No significant market-moving news for Johnson & Johnson in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Johnson & Johnson's stock performance. The company continues to maintain a stable position in the market.
No significant market-moving news for Johnson & Johnson in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Johnson & Johnson's stock performance. The company continues to focus on its core operations and ongoing initiatives.
Johnson & Johnson proposes $5.5 billion talc settlement to end lawsuits
Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging that its talc-based products caused ovarian cancer. This move aims to conclude over a decade of litigation, contingent upon at least 95% of claimants' participation. The company plans an initial payment of up to $3 billion in 2027, with no further payments due until 2028.
Johnson & Johnson proposes $5.5 billion talc settlement to end lawsuits
Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging that its talc-based products caused ovarian cancer. The settlement is contingent upon at least 95% of claimants agreeing to the terms. This move aims to conclude over a decade of legal disputes and allow the company to focus on its core medical and technological initiatives.
Johnson & Johnson proposes $5.5 billion talc settlement to end lawsuits
Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging that its talc products caused ovarian cancer. This move aims to conclude over a decade of litigation, contingent upon at least 95% of claimants' participation. The company plans an initial payment of up to $3 billion in 2027, with no further payments due until 2028.
Johnson & Johnson proposes $5.5 billion talc settlement to end lawsuits.
Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging that its talc products caused ovarian cancer. This move aims to conclude over a decade-long legal battle, contingent upon at least 95% of claimants accepting the offer. The company plans to make an initial payment of up to $3 billion in 2027, with no further payments due until 2028.
Johnson & Johnson proposes $5.5 billion talc settlement, stock rises over 2%.
Johnson & Johnson has proposed a $5.5 billion settlement to resolve ongoing lawsuits alleging its talc products caused ovarian cancer. This move aims to conclude over a decade of litigation and has positively impacted the company's stock, which rose more than 2% before the market opened.
Johnson & Johnson proposes $5.5 billion settlement to resolve talc lawsuits.
Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging that its talc products caused ovarian cancer. The settlement is contingent upon at least 95% of the remaining claimants participating. The company plans to make an initial payment of up to $3 billion in 2027, with no further payments due until 2028.
Johnson & Johnson proposes $5.5 billion settlement to resolve talc cancer lawsuits
Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 lawsuits alleging its talc products caused ovarian cancer. The settlement is contingent upon at least 95% of claimants participating. This move aims to conclude a decade-long legal battle and allows the company to focus on its core mission of developing life-saving medicines and devices.
Johnson & Johnson agrees to $5.5 billion settlement over talc-related cancer claims.
Johnson & Johnson has agreed to a $5.5 billion settlement to resolve approximately 69,000 lawsuits alleging that its talc-based products caused ovarian cancer. This settlement aims to efficiently conclude a prolonged legal battle that has been ongoing for over a decade.
No significant market-moving news for Johnson & Johnson (JNJ) in the past 24 hours.
Over the past 24 hours, there have been no major developments affecting Johnson & Johnson's stock performance. The company continues to maintain a stable position in the market.
Johnson & Johnson's Ottava Surgical Robot Receives FDA Approval, Stock Rises Nearly 2%
Johnson & Johnson's Ottava surgical robot has received FDA marketing authorization, marking the company's entry into the soft-tissue robotic-assisted surgery market. This development has positively impacted the stock, which rose nearly 2% following the announcement.
Bank of Nova Scotia reduces Johnson & Johnson stake by 36.3%
In the first quarter, Bank of Nova Scotia decreased its holdings in Johnson & Johnson by 36.3%, selling 433,751 shares and retaining 761,803 shares valued at approximately $186.2 million. This move comes after Johnson & Johnson reported better-than-expected quarterly results, including earnings per share of $2.90 and revenue of $25.31 billion, and raised its full-year 2026 guidance to an EPS of $11.60–$11.75.
Johnson & Johnson's stock rises 1.2% to $259.27 after strong Q2 earnings and dividend announcement.
Johnson & Johnson's stock price increased by 1.2% to $259.27 following the release of its second-quarter 2026 earnings report, which exceeded expectations. The company also declared a quarterly dividend of $1.34 per share, marking the 64th consecutive year of dividend increases.
Johnson & Johnson's OTTAVA robotic surgery system receives FDA approval, shares rise 2%
Johnson & Johnson's stock rose 2% following the FDA's approval of its OTTAVA robotic surgery system, marking a significant expansion into the surgical robotics market. Analysts have responded positively, with several firms raising price targets and issuing buy ratings. The company also reported solid fundamentals, including better-than-expected quarterly earnings and an increased dividend.
Johnson & Johnson's stock remains steady as investors await next catalyst.
In the past 24 hours, there have been no significant developments affecting Johnson & Johnson's stock. The company continues to trade near its 52-week high, with shares up 57% over the past year. Investors are awaiting upcoming earnings reports and potential catalysts to drive future stock performance.
Johnson & Johnson's stock remains steady amid Kenvue stake sale and pharma growth.
In the past 24 hours, Johnson & Johnson's stock has maintained stability, reflecting the company's ongoing transition following the 2023 Kenvue consumer-health separation. The latest quarterly results highlight mid-single-digit revenue growth and resilient margins, driven by expanding pharmaceutical and medtech operations.
PeakShares LLC invests $1.11 million in Johnson & Johnson (JNJ)
In the past 24 hours, there have been no significant market-moving developments for Johnson & Johnson (JNJ). The stock remains influenced by recent earnings reports and analyst evaluations.
Johnson & Johnson's stock rises 1.1% after strong Q2 earnings report
Johnson & Johnson's stock increased by 1.1% following the release of its Q2 2026 earnings report, which exceeded analysts' expectations. The company reported earnings per share (EPS) of $2.90, surpassing the consensus estimate of $2.84, and revenue of $25.31 billion, exceeding the anticipated $25.06 billion.
Johnson & Johnson's Q2 2026 earnings beat estimates; stock rises 1.2% to $255.66.
Johnson & Johnson reported strong Q2 2026 results, with earnings per share (EPS) of $2.90, surpassing analyst expectations of $2.84. The company also raised its 2026 guidance, projecting reported sales of $101.1 billion, a 7.3% increase at the midpoint. Despite these positive developments, the stock experienced a slight decline due to underperformance in the MedTech segment.
Johnson & Johnson's Q2 earnings beat expectations; stock price target raised to $261.
Johnson & Johnson reported strong second-quarter results, with earnings per share (EPS) of $2.90, surpassing analyst expectations. The company also raised its full-year 2026 revenue guidance to approximately $101.1 billion, marking a significant milestone. Additionally, J&J announced a $750 million restructuring plan to streamline its pharmaceutical supply chain.
Analysez n’importe quel graphique en quelques secondes
Voici la lecture du jour sur Johnson & Johnson. Pointez votre caméra vers n’importe quel graphique et ChartDetector AI vous livre une analyse technique complète en quelques secondes — gratuit sur iOS.
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.